About

RODI Fertility® is an award winning innovative research & development company focusing on the delivery of fertility solutions, that overturn the rules of a traditional approach to fertility. RODI Fertility was established in New York in 2018 as an R&D company and in 2020 in Athens. In 2022 commenced commercial operations deploying an innovative and revolutionary program with a suite of products which are the result of 7-years of clinical research. RODI Fertility® products support women with pregnancy difficulties and recurrent miscarriages to successfully navigate through the parenthood challenge as they incorporate a wide spectrum of studies and clinical experience on fertility. We are a community of scientists and researchers who have dedicated ourselves over the years to innovation, with great passion and deep-rooted vocation, aiming at developing accessible solutions that can positively impact women in their journey to motherhood.

Solution & Product

Specific immune cells appear to be the main cell population involved in cases of the so called allo-immune miscarriages where the embryo is recognized as foreign and is “rejected” by the mother. RODI NK plus is a formula with a patented technology, that contributes to the equilibrium of a potentially aggressive immune system function in the period before pregnancy and RODI NK is a woman's key ally during the first three months of pregnancy. RODI OVA™ provides an optimum selection and dosage of nutrients while your body works on delivering its eggs. Hormonal imbalances can change a woman’s reproductive health and negatively impact the outcome of family planning. FSH & LH are the two key hormones responsible for maturing an egg leading up to ovulation. An advanced formulation for day and night use containing a high-dose combination of several ingredients that contributes to the regulation of the hormonal activity. RODI VITA™ provides an optimum selection and dosage of essential prenatal vitamins and minerals during the period before trying for a baby. Its advanced pharmacokinetic based on its bilayer technology, convey its ingredients in two phases, achieving higher absorption, not obtainable with conventional tablets and gels. Two medical devices with FDA and CE approvals , a pregnancy test and a semiquantitative ovulation test.

Innovation & Scalability

Despite major advances in fertility, pregnancy challenges, and primarily miscarriages, continue to be a global health issue affecting millions of women. RODI Fertility taps into this pressing healthcare need in a large inelastic patient base of 17,5% of women suffering from infertility and at least 1 in 4 having a miscarriage and serves this huge emerging unmet need with two Patented products across all major global markets. The patents and our Freedom to operate guarantee a growth that can be sustained for a long period thus it provides a significant barrier to entry for any future competitor. Rodi Fertility's medical community will opts for expert referrals and will continuously use peer-to-peer presentations, attendance at congresses and a KOL development plan. New products are already under development with 2 new patents coming in by 2025.

Traction & achievements

In July 2020, Rodi Fertility won the ENVOLVE Award, a prestigious entrepreneurship award, which singled us out among 800 candidates for our innovation and high value-generating business model. In April 2019, Rodi Fertility received a scientific award at the Panhellenic Congress of Autoimmune Diseases, Rheumatology and Clinical Immunology for significant outcomes related to the results of a clinical study using RODI NK plus™. RODI Fertility has a robust, clinically studied efficacy for its products during a 7-year research. Has participated in 10 national and International Medical conferences announcing the results of its clinical studies, has publications and the product RODINK plus is already endorsed in the international medical bibliography. (Carp, H. (2020). Recurrent Pregnancy Loss Third Edition, CRC Press 2020.) Won Step 1 of EIC accelerator and is preparing for stage two. The founder has been awarded for her contribution to science by the America College of Greece, Senate of Rhode Island and was invited as a speaker in 2024 World Economic Forum.

Team & Why Us

RODI FERTILITY's products are considered a BLUE OCEAN Innovation. RODI NK plus & RODI NK, are first in class and first to market that act as immunomodulatory regulators. They are designed to prevent implantation failures and miscarriages, and are backed by clinical evidence with results visible in a simple blood test. With these products we hold an EXCLUSIVE MONOPOLY in the global fertility industry backed by patents in 53 countries. Our growth strategy focuses on securing binding distribution agreements with local and regional pharmaceutical companies for a duration of 3-5 years, based on annual minimum order quantities. Currently, we have established partnerships in 8 countries, with major players serving as our exclusive distributors. By the end of 2025, we anticipate expanding our reach to over 14 countries across Europe, the Middle East, and Asia, significantly amplifying our market presence and impact. RODI Fertility’s On line store in addition will service specific markets directly or in combination with the distributor.

Funding Needs

RODI Fertility is funding its scale-up activities through cash flow. To accelerate growth and expand its market presence in North America and the Asia-Pacific region, as well as to develop new products to enhance its portfolio, the company is seeking a strategic partnership with an investment of €5-7 million.